Skip to menu Skip to content Skip to footer

2020

Conference Publication

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

Sanchorawala, Vaishali, Palladini, Giovanni, Minnema, Monique C., Jaccard, Arnaud, Lee, Hans C., Gibbs, Simon D., Mollee, Peter, Venner, Christopher P., Lu, Jin, Schonland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Cibeira, M. Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania T. M., Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Chauveau, Dominique, Gries, Katharine S., Fastenau, John, NamPhuong Tran, , Qin, Xiang, Vasey, Sandra Y., Tromp, Brenda, Weiss, Brendan M. ... Wechalekar, Ashutosh D. (2020). Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-139438

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

2020

Conference Publication

The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukemia

Murali, Aarya, Cross, Donna and Mollee, Peter (2020). The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukemia. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. AMSTERDAM: American Society of Hematology. doi: 10.1182/blood-2020-140966

The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukemia

2020

Conference Publication

Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda

Comenzo, Raymond L., Kastritis, Efstathios, Palladini, Giovanni, Minnema, Monique C., Wechalekar, Ashutosh D., Jaccard, Arnaud, Sanchorawala, Vaishali, Lee, Hans C., Gibbs, Simon D., Mollee, Peter, Venner, Christopher P., Lu, Jin, Schonland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Cibeira, M. Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania T. M., Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Chauveau, Dominique, Dimopoulos, Meletios A., NamPhuong Tran, , Qin, Xiang, Vasey, Sandra Y. ... Merlini, Giampaolo (2020). Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda. 62nd Annual Meeting of the American-Society-of-Hematology (ASH), Electr Network, Dec 05-08, 2020. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2020-137582

Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda

2020

Conference Publication

An individualised, supervised exercise program is safe and feasible for patients with multiple myeloma: The MyeEx Study

Nicol, Jennifer L., Hill, Michelle M., Cunningham, Brent, Nunan, Elizabeth, Woodrow, Carmel, Keating, Eliza, Adlard, Kirsten, Smith, Michelle, Mollee, Peter, Weber, Nicholas, Nicol, Andrew J. and Skinner, Tina L. (2020). An individualised, supervised exercise program is safe and feasible for patients with multiple myeloma: The MyeEx Study. COSA's 47th Annual Scientific Meeting, Quality and Safety, Implementation Science, Cardio-Oncology, Virtual, 11–13 November 2020. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. doi: 10.1111/ajco.13499

An individualised, supervised exercise program is safe and feasible for patients with multiple myeloma: The MyeEx Study

2020

Conference Publication

Changing picture of ATTR wild type cardiomyopathy in Australia – Queensland Amyloidosis Centre experience

Korczyk, D., Woodcroft-Brown, V., Maffey, M. and Mollee, P. (2020). Changing picture of ATTR wild type cardiomyopathy in Australia – Queensland Amyloidosis Centre experience. 68th Cardiac Society of Australia and New Zealand Annual Scientific Meeting, the International Society for Heart Research Australasian Section Annual Scientific Meeting and the 14th Annual Australia and New Zealand Endovascular Therapies Meeting, Online, 11-13 December 2020. Chatswood, NSW Australia: Elsevier. doi: 10.1016/j.hlc.2020.09.100

Changing picture of ATTR wild type cardiomyopathy in Australia – Queensland Amyloidosis Centre experience

2020

Conference Publication

99Tc-DPD Bone scintigraphy correlates with left ventricular wall thickness and global longitudinal strain in patients with ATTR wild type cardiac amyloidosis

Robinson, J., Burrage, M., Ngai, S., Mackenzie, E., Duong, J., Mollee, P. and Korczyk, D. (2020). 99Tc-DPD Bone scintigraphy correlates with left ventricular wall thickness and global longitudinal strain in patients with ATTR wild type cardiac amyloidosis. 68th Cardiac Society of Australia and New Zealand Annual Scientific Meeting, the International Society for Heart Research Australasian Section Annual Scientific Meeting and the 14th Annual Australia and New Zealand Endovascular Therapies Meeting, Online, 11-13 December 2020. Chatswood, NSW Australia: Elsevier. doi: 10.1016/j.hlc.2020.09.069

99Tc-DPD Bone scintigraphy correlates with left ventricular wall thickness and global longitudinal strain in patients with ATTR wild type cardiac amyloidosis

2019

Conference Publication

Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone

Kalff, Anna, Khong, Tiffany, Ramachandran, Malarmathy, Norton, Sam, Mitchell, Andrew, Reynolds, John, Quach, Hang, Ho, P. Joy, Horvath, Noemi, Mollee, Peter, Kennedy, Nola, Kemp, Roslyn and Spencer, Andrew (2019). Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando Fl, Dec 05-10, 2019. AMSTERDAM: ELSEVIER. doi: 10.1182/blood-2019-130154

Identification of Novel Immune Cell Populations in Lenalidomide Refractory Relapsed Multiple Myeloma Patients Treated with Pomalidomide and Low Dose Dexamethasone

2019

Conference Publication

Daratumumab, lenalidomide, and dexamethasone (d-rd) delivers a reduction and delay in worsening of pain symptoms for patients with newly diagnosed multiple myeloma ineligible for transplant

Gries, Katharine, Facon, Thierry, Plesner, Torben, Usmani, Saad, Kumar, Shaji, Orlowski, Robert Z., Bahlis, Nizar J., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, Hulin, Cyrille, Weisel, Katja, He, Jianming, Ho, Kai Fai, Wang, Jim, Van Rampelbergh, Rian, Uhlar, Clarissa, Kobos, Rachel and Perrot, Aurore (2019). Daratumumab, lenalidomide, and dexamethasone (d-rd) delivers a reduction and delay in worsening of pain symptoms for patients with newly diagnosed multiple myeloma ineligible for transplant. 17th International Myeloma Workshop, Boston, MA, 12-15 September 2019. Dallas: CIG Media Group. doi: 10.1016/j.clml.2019.09.375

Daratumumab, lenalidomide, and dexamethasone (d-rd) delivers a reduction and delay in worsening of pain symptoms for patients with newly diagnosed multiple myeloma ineligible for transplant

2019

Conference Publication

Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based induction

Mollee, Peter, Boyle, Stephen, Wellard, Cameron, Moore, Elizabeth, Blacklock, Hilary, Harrison, Simon J., Ho, P. Joy, Hocking, Jay, McQuilten, Zoe, Quach, Hang, Spearing, Ruth, Wood, Erica and Spencer, Andrew (2019). Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based induction. 17th International Myeloma Workshop, Boston, MA United States, 12 - 15 September 2019. New York, NY United States: Elsevier. doi: 10.1016/j.clml.2019.09.388

Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based induction

2019

Conference Publication

Development of an individualized, supervised exercise intervention as standard care for patients with multiple Myeloma

Nicol, Jennifer, Woodrow, Carmel, Burton, Nicola, Hill, Michelle, Skinner, Tina, Mollee, Peter and Nicol, Andrew (2019). Development of an individualized, supervised exercise intervention as standard care for patients with multiple Myeloma. 17th International Myeloma Workshop, Boston, MA United States, 12-15 September 2019. New York, NY United States: Elsevier . doi: 10.1016/j.clml.2019.09.355

Development of an individualized, supervised exercise intervention as standard care for patients with multiple Myeloma

2019

Conference Publication

Significantly improved relative survival of patients with myeloma in Queensland with treatment advances

Mollee, Peter, Harwood, Matthew, Dunn, Nathan, Moore, Julie and Hapgood, Greg (2019). Significantly improved relative survival of patients with myeloma in Queensland with treatment advances. 17th International Myeloma Workshop, Boston, MA, 12-15 September 2019. Dallas: CIG Media Group. doi: 10.1016/j.clml.2019.09.387

Significantly improved relative survival of patients with myeloma in Queensland with treatment advances

2019

Conference Publication

Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

Blacklock, Hilary, Moore, Elizabeth, Wellard, Cameron, Harrison, Simon J., Ho, P. Joy, Hocking, Jay, McQuilten, Zoe, Mollee, Peter, Quach, Hang, Spearing, Ruth, Wood, Erica and Spencer, Andrew (2019). Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). 17th International Myeloma Workshop, Boston, MA, 12-15 September 2019. Dallas: CIG Media Group. doi: 10.1016/j.clml.2019.09.354

Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

2019

Conference Publication

Lysozyme amyloidosis – Two novel cases with newly described genetic mutations

McMichael, L., Chang, S., Gibbs, S., Mollee, P., Gillmore, J., Horvath, N., Crail, S. and Jobert, A. (2019). Lysozyme amyloidosis – Two novel cases with newly described genetic mutations. ISN World Congress of Nephrology (WCN) 2024, Buenos Aires, Argentina, 13-16 April 2024. New York, NY United States: Elsevier. doi: 10.1016/j.ekir.2019.05.590

Lysozyme amyloidosis – Two novel cases with newly described genetic mutations

2019

Conference Publication

Validation of the Boston University staging system in AL amyloidosis

Tomlinson, R., Matigain, N. and Mollee, P. (2019). Validation of the Boston University staging system in AL amyloidosis. 29th European Hematology Association Congress EHA24, Madrid, Spain, 13-16 June 2024. Philadelphia, PA United States: Wiley. doi: 10.1097/01.hs9.0000567024.85321.eb

Validation of the Boston University staging system in AL amyloidosis

2019

Conference Publication

The epidemiology of amyloidosis in Australia

Wisniowski, Brendan, McLeod, Donald, Adams, Rebecca, Harvey, Yasmin, Armes, Jane, Papadimos, David, Brown, Ian, McGuire, Lloyd and Mollee, Peter (2019). The epidemiology of amyloidosis in Australia. XVI International Symposium on Amyloidosis, Kumamoto, Japan, 26-29 March 2018. Abingdon, Oxfordshire United Kingdom: Taylor & Francis. doi: 10.1080/13506129.2019.1582481

The epidemiology of amyloidosis in Australia

2019

Conference Publication

Beta-migrating paraproteins: a need for harmonisation of reporting

Wijeratne, Nilika, Tate, Jillian R., Du Toit, Stephen, Smith, Joel D., Soepnel, Andrew, Choy, Kay Weng, Martin, Helen, Henry, Robyn, Glegg, Kaye, Byrnes, Elizabeth, Wienholt, Louise and Mollee, Peter (2019). Beta-migrating paraproteins: a need for harmonisation of reporting. Pathology Update 2019, Melbourne, VIC Australia, 22-24 February 2019. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.pathol.2018.12.323

Beta-migrating paraproteins: a need for harmonisation of reporting

2019

Conference Publication

Development of an individualized, supervised exercise intervention as standard care for patients with Multiple Myeloma

Nicol, Jennifer, Woodrow, Carmel, Burton, Nicola, Hill, Michelle, Skinner, Tina, Mollee, Peter and Nicol, Andrew (2019). Development of an individualized, supervised exercise intervention as standard care for patients with Multiple Myeloma. 17th International Myeloma Workshop, Boston, MA, United States, 12-15 September 2019. New York, United States: Elsevier. doi: 10.1016/j.clml.2019.09.355

Development of an individualized, supervised exercise intervention as standard care for patients with Multiple Myeloma

2018

Conference Publication

Activation of Fc Gamma Receptor-Dependent Responses to Therapeutic Antibodies By Nurse like Cells Requires PI3Kdelta

Chen, Yu-Chen Enya, Burgess, Melinda Lea, Blumenthal, Antje, Mapp, Sally, Mollee, Peter, Gill, Devinder and Saunders, Nicholas Andrew (2018). Activation of Fc Gamma Receptor-Dependent Responses to Therapeutic Antibodies By Nurse like Cells Requires PI3Kdelta. 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA United States, 1-4 December 2018. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-109719

Activation of Fc Gamma Receptor-Dependent Responses to Therapeutic Antibodies By Nurse like Cells Requires PI3Kdelta

2018

Conference Publication

The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular Lymphoma

Tobin, J., Keane, C., Mollee, P., Birch, S., Gould, C., Gunawardana, J., Hoang, T., Savarimuthu, S., Ma, T., Li, L., Murigneux, V. , Fink, L., Matigian, N. and Gandhi, M. K. (2018). The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular Lymphoma. RACP Congress 2018, Disruption for Healthy Futures, Sydney, NSW Australia, 14–16 May 2018. Hoboken, NJ United States: Wiley. doi: 10.1111/imj.2_13826

The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular Lymphoma

2018

Conference Publication

Perspectives on physical activity of clinical haematologists and their patients with multiple myeloma

Nicol, Jennifer L., Burton, Nicola W., Woodrow, Carmel, Mollee, Peter, Hill, Michelle M., Nicol, Andrew J. and Skinner, Tina L. (2018). Perspectives on physical activity of clinical haematologists and their patients with multiple myeloma. COSA's 45th Annual Scientific Meeting, Mesothelioma and Gastro‐Intestinal Cancers: Technology and Genomics, Perth, Western Australia, 13–15 November 2018. Hoboken, NJ United States: Wiley.

Perspectives on physical activity of clinical haematologists and their patients with multiple myeloma